Amphotericin Versus Posaconazole for Pulmonary Mucormycosis
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Pulmonary mucormycosis is a serious illness with high morbidity and mortality (approximately
57%). Surgery and antifungal therapy are central in the management of mucormycosis. Unlike
rhino-orbital mucormycosis, surgery is not feasible in several patients with pulmonary
mucormycosis. Hence, treatment is primarily with antifungal therapy. Amphotericin B is the
standard of care in the medical management of mucormycosis. However, amphotericin B is
expensive, has significant adverse events, and is available only in parenteral formulation.
Posaconazole is effective against Mucorales, and is currently approved for salvage therapy of
mucormycosis. Recent evidence suggest that in several patients, posaconazole may be effective
as a monotherapy upfront. In the current study posaconazole versus amphotericin B will be
evaluated for the management of pulmonary mucormycosis in a randomized clinical trial.
Phase:
Phase 2
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research
Treatments:
Amphotericin B Liposomal amphotericin B Posaconazole